Every 10-Q that Cormedix (CRMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CRMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRMD filings page.
CorMedix Inc. reported strong growth for the three and six months ended June 30, 2026, driven by DefenCath and the acquired Melinta infectious-disease portfolio. Total revenue and grant income reached $229.4 million for six months, up 191% year over year, with six‑month net income of $64.6 million, up 60%.
DefenCath generated six‑month product sales of $163.6 million, while Melinta products contributed $52.6 million. Grant income from the BARDA partnership was $5.1 million and contract revenue $8.0 million. Cash and cash equivalents were $256.7 million and total assets $904.1 million, partially funded by $150 million of 4.00% Convertible Senior Notes due 2030.
Gross profit and operating income more than doubled, despite higher R&D, selling, and G&A expenses tied to Melinta integration and portfolio expansion. Management notes a significant decline in DefenCath reimbursement after its TDAPA transition on July 1, 2026, which is expected to reduce net pricing and second‑half 2026 net sales.
CorMedix Inc. (CRMD) reported a profitable quarter and closed a transformative acquisition. Q3 2025 revenue was $104.3 million, driven by $101.5 million in product sales and $2.7 million in contract revenue. Gross profit reached $93.1 million and income from operations was $51.3 million. A tax benefit of $56.0 million contributed to net income of $108.6 million (basic EPS $1.42; diluted $1.26).
On August 29, 2025, CorMedix acquired Melinta, adding six marketed anti-infectives plus TOPROL‑XL and recording $390.0 million of intangible assets and $17.5 million of goodwill. Year‑to‑date, revenue was $183.1 million with net income of $149.0 million and operating cash flow of $80.6 million. To help fund the deal, the company issued $150.0 million 4.00% Convertible Senior Notes due 2030 and recognized $95.9 million of contingent consideration at fair value. Cash and cash equivalents were $48.5 million, stockholders’ equity was $374.1 million, and total assets were $750.9 million. Shares outstanding were 78,789,045 as of November 10, 2025.
CorMedix (CRMD) delivered its first profitable quarter since commercial launch of DefenCath. Q2-25 net sales surged to $39.7 m from $0.8 m a year ago, lifting H1 revenue to $78.8 m. Gross margin was 95% and operating income reached $19.5 m versus a $15.3 m loss in Q2-24; H1 operating income was $39.7 m. Net income came in at $19.8 m (-dil. EPS $0.28) for the quarter and $40.5 m for six months, despite a $2.0 m negative adjustment to Medicaid rebate estimates.
Liquidity strengthened sharply: cash and equivalents rose to $159.3 m and short-term investments to $31.4 m, driven by a $82.4 m June equity offering, $6.8 m ATM sales and $1.5 m option exercises. Stockholders’ equity climbed to $220.6 m from $84.7 m year-end.
Customer concentration remains high (Customer A 59% of Q2 sales; 45% of receivables). Gross-to-net deductions totalled $41.3 m YTD (52% of gross sales).
Strategic moves: • August 2025 agreement to acquire Melinta Therapeutics for $260 m cash + $40 m shares; closing expected Sept-25. • Parallel $150 m 4.0% senior convertible notes due 2030 to partly fund the deal. • OBBBA tax law change (July-25) expected to lower future cash taxes.
Balance sheet shows no long-term debt yet; pro-forma leverage will rise post-note issuance. Litigation (securities & derivative) continues, discovery stage.